Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
about
Androgen receptor (AR) in cardiovascular diseasesIntegrating Geriatric Assessment into Decision-Making after Prostatectomy: Adjuvant Radiotherapy, Salvage Radiotherapy, or None?Adverse effects of androgen deprivation therapy in men with prostate cancer: a focus on metabolic and cardiovascular complicationsIdentifying the unmet health needs of patients with congenital hypogonadotropic hypogonadism using a web-based needs assessment: implications for online interventions and peer-to-peer supportThe effects of opioids and opioid analogs on animal and human endocrine systemsNew therapy via targeting androgen receptor in monocytes/macrophages to battle atherosclerosis.Diet-induced obesity and low testosterone increase neuroinflammation and impair neural functionEnergetics in colorectal and prostate cancer.The use of dietary supplements to alleviate androgen deprivation therapy side effects during prostate cancer treatmentAndrogen Deprivation Therapy and Future Alzheimer's Disease RiskCardiovascular risk during hormonal treatment in patients with prostate cancer.Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy.Sex-specific effects of high fat diet on indices of metabolic syndrome in 3xTg-AD mice: implications for Alzheimer's disease.Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis.What do prostate cancer patients die of?The current practice of screening, prevention, and treatment of androgen-deprivation-therapy induced osteoporosis in patients with prostate cancer.Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancerCorrelation of serum testosterone with insulin resistance in elderly male type 2 diabetes mellitus patients with osteoporosis.Testosterone and cardiovascular disease in men.IL-1β, RAGE and FABP4: targeting the dynamic trio in metabolic inflammation and related pathologies.Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.Metabolic toxicities in patients undergoing treatment for nonhematological malignancy: A cross-sectional study.Sex steroids and glucose metabolism.Endothelial dysfunction and erectile dysfunction in the aging man.Clinical use of GnRH agonists in canine and feline species.Peripheral arterial ischemic events in cancer patients.Androgen regulation of prostate cancer: where are we now?Androgen deficiency in heart failure.New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.When and when not to use testosterone for palliation in cancer care.Triptorelin in the Relief of Lower Urinary Tract Symptoms in Advanced Prostate Cancer Patients: The RESULT Study.Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?[Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists].Cardiovascular Disease Risk Factors: How Relevant in African Men With Prostate Cancer Receiving Androgen-Deprivation Therapy?Short-Term Estrogen Withdrawal Increases Adiposity in Healthy Men.The side effects of hormonal therapy at the patients with prostate cancerTestosterone, HDL and cardiovascular risk in men: the jury is still out.Time to raise awareness regarding complications of androgen deprivation therapy.Adherence to treatment in men with hypogonadotrophic hypogonadism.Estrogens and Body Weight Regulation in Men.
P2860
Q26771962-5385EFEA-8D48-4609-B681-8CEB75121ADFQ26777128-BDCDFE26-0C96-426A-B8F7-362508474944Q26852930-A5A3F926-63B7-4EDD-A817-8E815365705BQ27498992-35792CB5-2D61-4A35-94E0-A02FB9832CB8Q33779667-60E508CB-14AF-4462-B2CF-A2C07D439FD9Q33842431-21AA7D47-9201-4440-8F45-893E652D4626Q34309465-A25D93B4-C078-4739-8B10-18411CDFAE25Q34315768-3FF6E85D-863F-498E-9DC9-01F7966EB09FQ34411758-FA765AC3-5479-49A1-A8E7-F2A1DD84B170Q34504328-E6B07C19-7085-4243-B346-2368DD72847CQ34721165-C34AE217-EB11-48CD-9F6D-49D7003EB9BDQ34943307-E1AEB59D-C872-473B-BB96-1DD2509355FCQ35036518-7216D4F3-9FB4-4727-96F2-5D419C8991A8Q35202889-A762845F-1531-44FB-AF2E-9CA888D75CD2Q35584421-430FE35D-2EC4-42D8-A62D-F234FEE6E741Q35954808-7472D0BA-BB4D-4C2F-AC2E-F382E00BBE52Q35977154-880A6463-1D30-45EC-814B-EEF4D21B24CCQ36082243-50B88C14-5EC5-45B6-A771-407962C1C6F5Q37037827-CCA6C365-5FF7-4D4C-AF11-8A5203D17E93Q37305013-0CAFEF7F-6BF4-43FF-8C5E-60E48ADC9FA0Q37331782-AA858479-969D-450B-AE88-33AF517488D8Q37584924-EC4BE9BE-A077-46A8-ACAC-697EC055E7B4Q37639198-3B5DF474-3D79-4343-889A-DB5E497DB273Q37650850-FEC0F961-19DF-41DC-BCAE-7541217C6BEBQ37801976-221B54D9-EF7F-4370-A14B-B14F9E396D46Q37812994-240552CE-FEF5-40F4-9799-6324AEC395A9Q37836264-E1193A3D-7498-4F6C-9FFC-49C728E8A8A7Q37851063-7CF41464-A795-4E57-999F-C3C6DF54232AQ38023124-EDD37FD5-3CE1-44A6-ABD4-C73A7A5ED6EBQ38186655-92BC4034-C0FF-4C4C-B80F-A759D96231DAQ39193963-539192F4-041D-4636-9F8B-CEF24761152CQ39815205-B83C0513-A066-4EE9-8B5C-A02E44E10735Q40797796-704F3728-BD85-4538-97D2-85F7C53449F5Q40988056-4225342A-D091-485B-9D3D-4F536A83C2E3Q41646633-098BB157-FFFE-4D16-87E0-5560E83F887CQ41859896-1A4F09B6-2E66-4984-A57A-B886357D5FECQ41894033-4ACD584C-036C-43AF-A728-C18DF81CC402Q42540245-9F3F5EF5-BB40-466A-B661-AD58AF695285Q46888939-6DE83A26-00ED-40D2-B990-889229FDFB83Q47174327-E5BC6954-407C-429F-9B5B-D5406555F7BE
P2860
Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
@en
Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
@nl
type
label
Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
@en
Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
@nl
prefLabel
Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
@en
Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
@nl
P2093
P356
P1476
Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
@en
P2093
Milena Braga-Basaria
Sadeka Shahani
Shehzad Basaria
P304
P356
10.1210/JC.2007-2595
P407
P577
2008-03-18T00:00:00Z